Intellia Therapeutics recently announced that the FDA has cleared an Investigational New Drug application for NTLA-2002, a single-dose in vivo CRISPR...
In this update, we summarise the two ongoing gene-editing clinical trials for renal cell carcinoma, which is the most common form of kidney cancer...
Verve Therapeutics announced yesterday that its most advanced base-editing candidate VERVE-101 has been awarded the Innovation Passport for the...
Last week, Allogene Therapeutics announced the publication of data from the Phase 1 UNIVERSAL trial of ALLO-715, a TALEN-engineered CAR-T candidate...
In this clinical update, we look at four ongoing clinical trials involving a gene-edited therapeutic candidate for the treatment of solid cancers.
To mark the start of 2023, we look back on some of the key advances in gene-editing clinical trials from 2022.
Caribou Biosciences has reported new 12-month clinical data from its ongoing ANTLER Phase 1 trial of CB-010 for relapsed/refractory B cell non-Hodgkin...
In this piece, we bring a summary of the latest clinical data from Editas Medicine's ongoing RUBY trial for EDIT-301 in severe sickle cell disease, as...
